Overview
PFE market data
Price History
PFE price chart
Valuation & Profitability
- P/E (TTM)
- 35.19 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $1.36 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.28 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 6.4% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 6.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $23.58 – $28.75 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $152.5B · P/B 1.64 · P/S 2.39.
Company News
AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool · Aug 14, 2026, 8:30 PM
European Regulator Validates Pfizer and Valneva's Lyme Disease Vaccine ApplicationBenzinga · Aug 14, 2026, 4:46 PM
Eli Lilly Just Scored Europe's First Weight Loss Pill Approval -- and the Growth Story Keeps Getting BiggerThe Motley Fool · Aug 14, 2026, 3:46 PM
Recent Filing Shows That Rep. Carol Miller Sold Over $60K Worth of Pfizer StockBenzinga · Aug 14, 2026, 3:02 PM
Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving PremarketBenzinga · Aug 14, 2026, 8:37 AM
Pfizer And Valneva's Lyme Disease Vaccine Candidate PF-07307405 Clears EMA Validation Of Marketing Authorization Application After Phase 3 VALOR Trial Showed More Than 70% EfficacyBenzinga · Aug 14, 2026, 5:06 AM
Big Pharma's Future Growth Rests on Chinese Science? Expert Says: 'We Can't Ban Our Way Out of This'Benzinga · Aug 13, 2026, 2:41 AM
AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool · Aug 11, 2026, 9:01 PM
Trump Says Administration Recognizing Childhood Vaccine Recommendations For Only 11 Core Vaccinations; Hepatitis B, COVID-19, Influenza No Longer Recommended For All ChildrenBenzinga · Aug 10, 2026, 7:00 PM
Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's ZepboundThe Motley Fool · Aug 7, 2026, 8:15 PM